SLC5A2 and cardiovascular disorder: Our work suggests novel cellular mechanisms underlying the observed clinical benefits of SGLT2 inhibitors; further characterization of the mechanistic effects of the SGLT2 inhibitor drug class on the human myocardium will broaden their use and indications in cardiovascular disease more efficiently.